Search Results - "Altunay, Betül"

Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting.

Authors: Altunay, Betül Obradović, Luka Florea, Alexandru et al.

Source: Scientific Reports. 11/4/2025, Vol. 15 Issue 1, p1-9. 9p.

Diagnostic Efficacy of FAPI-PET/CT Versus [ 18 F]FDG-PET/CT in Upper-Abdominal Malignancies: A Systematic Review and Meta-Analysis.

Authors: Huang, Hao Altunay, Betül Schäfer, Laura et al.

Source: Diagnostics (2075-4418). Feb2026, Vol. 16 Issue 4, p520. 17p.

Correction to: HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.

Authors: Altunay, Betül Morgenroth, Agnieszka Beheshti, Mohsen et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Sep2024, Vol. 51 Issue 11, p3485-3485. 1p.

Nectin-4–Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review.

Authors: Schäfer, Laura Altunay, Betül Morgenroth, Agnieszka et al.

Source: Journal of Nuclear Medicine. Mar2026, Vol. 67 Issue 3, p334-340. 7p.

Current Approaches of Nuclear Molecular Imaging in Breast Cancer.

Authors: Schäfer, Laura Altunay, Betül Heesch, Amelie et al.

Source: Cancers. Jul2025, Vol. 17 Issue 13, p2105. 28p.

^99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types.

Authors: Altunay, Betül Goedicke, Andreas Winz, Oliver H. et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Mar2023, Vol. 50 Issue 4, p1005-1013. 9p. 2 Color Photographs, 2 Charts, 3 Graphs.

HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.

Authors: Altunay, Betül Morgenroth, Agnieszka Beheshti, Mohsen et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. May2021, Vol. 48 Issue 5, p1371-1389. 19p. 2 Color Photographs, 2 Diagrams, 3 Charts.